Author

Tobias V. Lanz

h-index 5 View on Semantic Scholar

We have 2 of 15 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial

Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to...

Jason Xu, Chun-Li Mei, Xin Guan et al. · Nature Medicine · 0 citations

Open access Jul 2026

BTK Inhibition Resets Pathological B and T cell Subsets in Patients with IgG4-Related Disease 2258804

IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder marked by tissue infiltration of IgG4+ plasmablasts (PB) and elevated serum IgG4 levels. Bruton’s Tyrosine Kinase inhibition (BTKi) blocks key signaling pathways in B cells and showed promising efficacy in other autoimmune diseases. This is the first...

Tobias V. Lanz, Saurabh Gawde, Matthew C Baker · Journal of Immunology · 0 citations